The company depends on third parties, including contract laboratories, contract research organizations, medical institutions, clinical investigators, and other collaborators, to conduct preclinical studies and clinical trials for GLIX1 and motixafortide, as it lacks the capacity to perform these activities independently. These third parties may not meet performance expectations or deadlines, potentially resulting in delays and increased costs. The company has out-licensing agreements with Gloria and Ayrmid for later-stage development, marketing, or commercialization, which involve risks related to the level of control over resources allocated by these licensees.
Biolinerx Ltd's Comment on Supply Chain
The company depends on third parties, including contract laboratories, contract research organizations, medical institutions, clinical investigators, and other collaborators, to conduct preclinical studies and clinical trials for GLIX1 and motixafortide, as it lacks the capacity to perform these activities independently. These third parties may not meet performance expectations or deadlines, potentially resulting in delays and increased costs. The company has out-licensing agreements with Gloria and Ayrmid for later-stage development, marketing, or commercialization, which involve risks related to the level of control over resources allocated by these licensees.
Sources:
Biolinerx Ltd 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Biolinerx Ltd ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
